首页>投融资
Alvotech
IPO后其他轮次
Alvotech于2021年8月23日根据卢森堡大公国法律注册成立。该公司是一家生物技术公司,由Robert Wessman创立,专注于为全球患者开发和制造生物仿制药。该公司通过提供高质量、具有成本效益的产品和服务,通过完全集成的方法和广泛的内部能力来寻求成为生物仿制药领域的全球领导者。该公司目前的产品线包含八种生物仿制药候选药物,旨在治疗自身免疫性疾病、眼部疾病、骨质疏松症、呼吸系统疾病和癌症。
基本信息
-
公司全称Alvotech Holdings SA
-
类型生物仿制药研发、生产商
-
产业领域医药研发/制造
-
公司人数500人以上
-
地址9 Rue de Bitbourg L-1273 Luxembourg Grand Duchy of Luxembourg
-
联系电话354-4224500
-
邮箱
-
成立时间2013-01-01
投融资
-
2023-07-31IPO后其他轮次1亿美元未透露
-
2023-04-11IPO后其他轮次6275万美元Mitsui & Co
-
2023-01-23IPO后其他轮次1.37亿美元未透露
-
2022-12-16IPO后其他轮次5970万美元未透露
-
2022-11-16IPO后其他轮次1.36亿美元Farallon Capital ManagementSculptorMorgan StanleyOaktree Capital ManagementLodbrok CapitalAlvogen
-
2022-06-16上市未透露未透露
-
2021-12-07未公开未透露Oaktree Acquisition Corp. II
-
2021-03-15未公开3500万美元未透露
-
2020-10-27未公开6500万美元Aztiq PharmaBaxter VenturesATHOS ServiceShinhan CapitalAlvogen
-
2019-01-22债权融资3亿美元未透露
-
2018-12-17未公开5000万美元Fuji Pharma
- 加载更多
相关投融资企业
战略投资
Medic Life Sciences Inc是一家美国的生物技术公司,专注于开发创新的医疗设备和诊断技术。公司致力于改善患者的诊断和治疗体验,通过提供高效、便捷的医疗产品和服务,满足医疗市场的需求。其主要产品线包括医疗影像设备、诊断试剂和生物信息学工具等,通过不断的技术创新和市场拓展,为全球患者带来更好的医疗健康
收并购
Alderley Analytical is an independent Contract Research Organisation (CRO). We offer specialist bioanalytical services to support your drug development programmes, from discovery through to late stage clinical development, focusing on small molecules, large molecules, peptides, biologics and biomarkers.
Our biotech, pharma and CRO clients have discovered that keeping their bioanalysis with one provider means fewer laboratory transfers and no loss of bioanalytical knowledge of the molecule. By simplifying this process, it means less complications helping the rapid development of new drugs.
We take a flexible and responsive approach, using our collective expertise to develop novel bioanalytical methods and deliver your results on-time to the right quality. We also pride ourselves on excellent communication; you’ll find us easy to get hold of and we stay in touch, even if there’s no news to report.
As a GLP and GCP accredited laboratory, we can offer regulatory compliance where needed and are able to validate bioanalytical methods and deliver bioanalytical results to current FDA/EMA guidelines. Get in touch to discuss your bioanalysis requirements today.
Visit our website at www.alderleyanalytical.com for more information.
增发
Theriva Biologics, Inc.成立于1986年,是一家生物技术公司,专注于合成DNA为基础的疗法和治疗严重疾病的创新型疾病缓解药物的发展。该公司是一家多元化的临床阶段公司,开发旨在治疗高度未满足需求领域疾病的疗法。公司通过收购VCN Biosciences,SL进入肿瘤学领域,VCN Biosciences,SL开发了一种新的溶瘤腺病毒平台,设计用于静脉、玻璃体内和抗肿瘤递送以触发肿瘤细胞死亡,改善共同给药的癌症疗法对肿瘤的获取,并促进患者免疫系统产生强大而持续的抗肿瘤反应。